sigvotatug vedotin

Phase 3Antibody–drug conjugate

sigvotatug vedotin is one of 120 small molecule programs targeting Carcinoma, Non-Small-Cell Lung. It is currently in Phase 3.

Indications

Total Trials

Active Trials

119

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carcinoma, Non-Small-Cell LungActive, not recruiting

Non-Small Cell Lung CarcinomaRecruiting

Non-Small Cell Lung CancerRecruiting

Carcinoma, Non-Small-Cell LungPhase 3

Active, not recruiting

Non-Small Cell Lung CarcinomaPreclinical

Recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 3

14 2

Savolitinib

AstraZeneca

Phase 3

4 3

sigvotatug vedotin

Pfizer

Phase 3

1 4

Ds-1062a

Daiichi Sankyo

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatment

1 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06012435

Q1 2029

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06758401

Phase 1Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04389632

Q3 2033

PreclinicalRecruiting

Non-Small Cell Lung Carcinoma

NCT07227298

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT06012435·762 enrolled

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT04389632·1,006 enrolled

Advanced Solid Tumors1 trial

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Completed· Pfizer logo

Pfizer·Phase 1·NCT06549816·6 enrolled

Non-Small Cell Lung Carcinoma1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting· Pfizer logo

Pfizer·Preclinical·NCT07227298·162 enrolled

Non-Small Cell Lung Cancer1 trial

AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06758401·714 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for sigvotatug vedotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sigvotatug vedotin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sigvotatug vedotin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Pfizer

sigvotatug vedotin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Q3 2033

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung2 trials

Advanced Solid Tumors1 trial

Non-Small Cell Lung Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News